CHI’s Second Annual Bispecific Case Studies & Clinical Relevance conference will bring together clinicians, regulators, and industry experts in the field to discuss and exchange ideas on promising bispecific candidates. We will showcase all
crucial topics from understanding the biology behind different bispecific constructs to mitigating challenges in advancing novel platforms to the clinic. A companion diagnostic aspect for bispecific platforms will be examined for meaningful therapeutic
selection based on patient identification, stratification, and the early assessment of treatment efficacies. An extension of bispecific applications in other diseases besides oncology will also be discussed.
Preliminary Agenda
Introduction and Overview of Bispecific Antibodies in The Clinic
Rakesh Dixit, Vice President, Global Head, MedImmune, Inc.
ABL001 (NOV1501): A Novel Bispecific Antibody Targeting VEGF & DLL4 for the Treatment of Solid Tumors
Sang Hoon Lee, PhD, CEO, ABL Bio
Lessons Learned From the Bis4Ab platform: From a Bispecific Engineering Concept to Clinical Investigation.
Nazzareno Dimasi, PhD Associate Director R&D MedImmune
Leveraging Host Anti-Tumor Immunity through Bi-Specific DART® Molecule
Paul A. Moore, PhD, Vice President, Cell Biology & Immunology, MacroGenics, Inc.
M7824 (MSB0011359C), A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Advanced Solid Tumors
Julius Strauss, MD, Assistant Research Physician, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, NCI, NIH
Bioassay Development for Bispecific Antibody from an FDA Standpoint
Wen Jin Wu, MD, PhD, Senior Investigator, Office of Biotechnology Products, Center for Drug Evaluation and Research, FDA CDER
Design Meets Biology – Engineering a PD-1/CTLA-4 Bispecific Antibody to Improve Both Safety and Efficacy
Yariv Mazor, PhD, Senior Scientist, Antibody Discovery & Protein Engineering, MedImmune
Tumor Microenvironment and Its Impact on Bispecifics
Tariq Ghayur, PhD, Distinguished Research Fellow, Immunology Discovery, AbbVie
Clinical Pharmacology Considerations of Bispecific Antibodies
Ping Ji, PhD, Pharmacologist, OCP, FDA
Immunogenicity Assessment of Bispecific Antibody Therapeutics in Clinical Studies
Kate Peng, PhD, Group Leader/Senior Scientist, BioAnalytical Sciences, Genentech
For more details on the conference, please contact:
Emily Le
Conference Producer
[Cambridge Healthtech Institute]
Phone: 781-247-1812
Email: ele@healthtech.com
For partnering and sponsorship information, please contact:
Companies A-K
Jason Gerardi
Senior Manager, Business Development
[Cambridge Healthtech Institute]
Phone: 781-972-5452
Email: jgerardi@healthtech.com
Companies L-Z
Carol Dinerstein
Senior Manager, Business Development
[Cambridge Healthtech Institute]
Phone: 781-972-5471
Email: dinerstein@healthtech.com